Web Stats Provided By Google Analytics

Monday, January 8, 2018

Sanofi and Regeneron to accelerate and expand investment for...

Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs Companies also announce submission of dupilumab supplemental BLA for uncontrolled, persistent asthma Paris and Tarrytown, N.Y. - January 8, 2018 - Sanofi and Regeneron Pharmaceuticals, Inc. will accelerate and expand investment for the clinical development of the PD-1 antibody cemiplimab in oncology and dupilumab in Type 2 allergic diseases. Both of these breakthrough therapies have the potential to benefit a number of different patient populations and this strategic investment will enable the companies to evaluate cemiplimab and dupilumab in broad clinical development programs.
http://ift.tt/2qHO9x6

No comments:

Post a Comment

Popular Tarrytown Roundup Posts